“CRISPR babies”: What does this mean for science and Canada?

Knoppers, Bartha Maria; Kleiderman, Erika

doi:10.1503/cmaj.181657

Cited by 10 publications

(3 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…85 The apprehension about unnatural selection for unethical purposes has become more recognized in public perception because of the enormous media coverage surrounding the edited "CRISPR babies". 86 Keeping it in view, the regulatory bodies worldwide like FDA in USA and EMA in Europe are tasked with setting guidelines to balance such an innovation with ethical considerations and regulatory compliances. The need of the time is to have a call for an accurate, accountable and humanistic monitoring ensuring that CRISPR gene editing technology is used responsibly and for the maximum benefits of mankind.…”

Section: Ethical Concernsmentioning

confidence: 99%

CRISPR/Cas9-mediated genome editing: from basic research to gene therapy

Goel

2024

Int J Res Med Sci

View full text Add to dashboard Cite

CRISPR/Cas9 mediated genome editing is one of the most significant molecular tools discovered to edit the desired genes. It has ushered in a new era of novel possibilities of gene therapy. CRISPR/Cas9 system was originally observed as a part of the adaptive immune system in bacteria. It later on was adapted to carry precise and targeted alterations to the DNA in human cells to be used for gene therapy to correct genetic disorders and treat various severe diseases associated with the genetic changes. Besides this, the CRISPR/Cas9 system has been employed in pharmacogenomics to develop new drugs based on the patient’s genes, in modifying the organisms for research and even for diagnostic purposes in developing CRISPR based COVID-9 test. The recent approval of a CRISPR/Cas9 cellular gene therapy by FDA named “Casgevy” to treat sickle cell anemia is a testimonial to the potentials of CRISPR/Cas9 system in developing innovative gene therapies. This review details the mechanisms of CRISPR/Cas9 gene editing and its utilization in the ongoing clinical trials in the treatment of not only the monogenic disorders like sickle cell disease, thalassemia, and genetic blindness but also in treating multi-factorial diseases like cancers, cardiac diseases, diabetes, autoimmune diseases, viral infections such as human immunodeficiency virus (HIV) etc. An attempt has also been made to discuss the various limitations, challenges and ethical frameworks encompassing CRISPR/Cas9 based gene therapy in clinical settings.

show abstract

Section: Ethical Concernsmentioning

confidence: 99%

CRISPR/Cas9-mediated genome editing: from basic research to gene therapy

Goel

2024

Int J Res Med Sci

View full text Add to dashboard Cite

show abstract

“…I am responding to the recent CMAJ commentary by Dr. Bartha Maria Knopper and Erika Kleiderman. 1 The genomics revolution has opened Pandora's box for all life forms and continues to present challenges at every breakthrough. It pushes the boundaries of what is possible and acceptable.…”

Section: Lulu and Nana Open Pandora's Box Far Beyond Louise Brownmentioning

confidence: 99%

Lulu and Nana open Pandora’s box far beyond Louise Brown

Singh

2019

CMAJ

View full text Add to dashboard Cite

“…In response, the Chinese government has issued new draft regulations that would tighten oversight for “high-risk biomedical technologies,” which includes gene editing (18). Canadian regulatory reform discussions should take notice of this event, but not be overly influenced by it (19).…”

Section: Introductionmentioning

confidence: 99%

Canada's Assisted Human Reproduction Act: Pragmatic Reforms in Support of Research

et al. 2019

Self Cite

View full text Add to dashboard Cite

Canada's Assisted Human Reproduction Act is long overdue for Parliamentary review. We argue that the current regulation of research using human reproductive materials is not proportionate, not responsive to the uncertain threats posed to human and environmental health and safety, and is not considerate of diverse values in a democratic society. We propose tailored regulatory carve-outs for in vitro research for currently prohibited activities, such as gene editing, and for the exercise of Ministerial Discretion for access by Canadians to experimental in vivo interventions that are currently prohibited, such as mitochondrial replacement therapy. Our recommendations are bounded by constitutional constraints that recognize political and practical challenges in keeping oversight of this research under Federal jurisdiction, whether conducted in academic or private sectors. The proposed nuanced regulatory scheme should be overseen by a new national Agency, modeled on a blend of the Canadian Stem Cell Oversight Committee and Assisted Human Reproduction Canada.

show abstract

“CRISPR babies”: What does this mean for science and Canada?

Cited by 10 publications

References 6 publications

CRISPR/Cas9-mediated genome editing: from basic research to gene therapy

CRISPR/Cas9-mediated genome editing: from basic research to gene therapy

Lulu and Nana open Pandora’s box far beyond Louise Brown

Canada's Assisted Human Reproduction Act: Pragmatic Reforms in Support of Research

Contact Info

Product

Resources

About